All In Biotech

Drug Trial Radar · NCT03872947

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

138

Actual

Start

Apr 26, 2019

Primary completion

Jul 16, 2026

Study completion Jul 16, 2026

Sponsor

Lead sponsor
Toray Industries, IncIndustry
Sponsor type
Industry
First posted
Mar 13, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to establish the safety and the recommended dose of TRK-950 in combination with FOLFIRI, Gemcitabine / Cisplatin, Gemcitabine / Carboplatin, Ramucirumab / Paclitaxel, PD1 inhibitors (Nivolumab or Pembrolizumab), and Imiquimod Cream, Bevacizumab, Gemcitabine / Carboplatin / Bevacizumab, Pegylated liposomal doxorubicin (PLD), Carboplatin / PLD / Bevacizumab and Paclitaxel for selected advanced solid tumors.

Conditions

  • Solid Tumor
  • Colorectal Cancer
  • Cholangiocarcinoma
  • Bladder Cancer
  • Ovarian Cancer
  • Gastric Cancer
  • Palpable Subcutaneous Malignant Lesions
  • Renal Cell Carcinoma
  • Melanoma
  • Epithelial Ovarian Cancer
  • Primary Peritoneal Cancer
  • Fallopian Tube Cancer

Interventions

  • TRK-950Biological

    10 mg/kg administered intravenously over 60 minutes (weekly)

  • TRK-950Biological

    5 mg/kg administered intravenously over 60 minutes (weekly)

  • TRK-950Biological

    Treatment Phase: 20 mg/kg administered intravenously over 60 minutes (bi-weekly) Maintenance Phase: 30 mg/kg administered intravenously over 60 minutes (every 3 weeks)

  • IrinotecanDrug

    Intravenously over 30 - 90 minutes

  • LeucovorinDrug

    Intravenously over 30 - 90 minutes

  • 5-FUDrug

    Intravenously bolus and intravenously for two days

  • GemcitabineDrug

    Intravenously over 30 minutes

  • CisplatinDrug

    Intravenously over 60 minutes

  • CarboplatinDrug

    Intravenously per package insert

  • RamucirumabDrug

    Intravenously over 60 minutes

  • PaclitaxelDrug

    Intravenously

  • NivolumabDrug

    Intravenously over 30 minutes

  • PembrolizumabDrug

    Intravenously over 30 minutes

  • Imiquimod CreamDrug

    Topically

  • BevacizumabDrug

    Intravenously over 90 minutes for the first dose, over 60 for the second dose and over 30 minutes for all subsequent doses

  • PLDDrug

    Intravenously over 60 minutes

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of patients experiencing treatment emergent adverse events as assessed by CTCAE v5.0Time frame: through study completion, an average of 1 year
  2. Frequency of patients experiencing adverse events of special interest (AESIs)Time frame: through study completion, an average of 1 year
  3. Blood pressureTime frame: through study completion, an average of 1 year
  4. Heart rateTime frame: through study completion, an average of 1 year
  5. Respiratory rateTime frame: through study completion, an average of 1 year
  6. TemperatureTime frame: through study completion, an average of 1 year
  7. WeightTime frame: through study completion, an average of 1 year
  8. HeightTime frame: through study completion, an average of 1 year
  9. Performance status using Karnofsky performance status criteriaTime frame: through study completion, an average of 1 year
  10. QTc interval determined from 12-lead ElectrocardiogramTime frame: through study completion, an average of 1 year
  11. QRS interval determined from 12-lead ElectrocardiogramTime frame: through study completion, an average of 1 year
  12. Frequency of patients with laboratory abnormalities (Complete Blood Count, Coagulation, Urinalysis and Serum Chemistry)Time frame: through study completion, an average of 1 year

Locations

14 sites in 2 countries. Site status is shown where the registry gives one.

  • HonorHealth Research Institute

    Scottsdale, Arizona

  • AOA-HOPE

    Tucson, Arizona

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California

  • HOAG Memorial Hospital Presbyterian

    Newport, California

  • Ochsner Clinic Foundation

    New Orleans, Louisiana

  • Atlantic Health System

    Morristown, New Jersey

  • Perlmutter Cancer Center at NYU Langone

    New York, New York

  • Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute and Research Center)

    Eugene, Oregon

  • Northwest Cancer Specialists

    Portland, Oregon

  • Texas Oncology, P.A. Baylor Charles A. Sammons Cancer Center

    Dallas, Texas

  • Texas Oncology - Downtown Fort Worth Cancer Center

    Fort Worth, Texas

  • Virginia Cancer Specialists, PC

    Leesburg, Virginia

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Centre Léon Bérard

    Lyon, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.